Resistant Hypertension: Novel Insights.
Lamirault G, Artifoni M, Daniel M, Barber-Chamoux N, Nantes University Hospital Working Group On Hypertension.
Curr Hypertens Rev. 2020;16(1):61-72. doi: 10.2174/1573402115666191011111402.
[Reverse white-coat hypertension].
Inenaga T, Kawano Y.
Nihon Rinsho. 2006 Aug;64 Suppl 6:73-8.
'Reverse white-coat hypertension' in older hypertensives.
Wing LM, Brown MA, Beilin LJ, Ryan P, Reid CM; ANBP2 Management Committee and Investigators. Second Autralian National Blood Pressure Study.
J Hypertens. 2002 Apr;20(4):639-44. doi: 10.1097/00004872-200204000-00020.
Reverse white-coat effect as an independent risk for left ventricular concentric hypertrophy in patients with treated essential hypertension.
Tomiyama M, Horio T, Kamide K, Nakamura S, Yoshihara F, Nakata H, Nakahama H, Kawano Y.
J Hum Hypertens. 2007 Mar;21(3):212-9. doi: 10.1038/sj.jhh.1002127. Epub 2006 Dec 14.
Reversed white-coat hypertension: definition, mechanisms and prognostic implications.
Mancia G.
J Hypertens. 2002 Apr;20(4):579-81. doi: 10.1097/00004872-200204000-00006.
White-Coat and Reverse White-Coat Effects Correlate with 24-h Pulse Pressure and Systolic Blood Pressure Variability in Children and Young Adults.
Fujita H, Matsuoka S, Awazu M.
Pediatr Cardiol. 2016 Feb;37(2):345-52. doi: 10.1007/s00246-015-1283-5. Epub 2015 Oct 20.
Reverse white-coat effect as an independent risk for microalbuminuria in treated hypertensive patients.
Kato T, Horio T, Tomiyama M, Kamide K, Nakamura S, Yoshihara F, Nakata H, Nakahama H, Kawano Y.
Nephrol Dial Transplant. 2007 Mar;22(3):911-6. doi: 10.1093/ndt/gfl642. Epub 2006 Dec 1.
White-coat effect in normotension and hypertension.
Zakopoulos NA, Kotsis VT, Pitiriga VCh, Toumanidis ST, Lekakis JP, Nanas SN, Vemmos KN, Stamatelopoulos SF, Moulopoulos SD.
Blood Press Monit. 2002 Oct;7(5):271-6. doi: 10.1097/00126097-200210000-00004.
White-coat hypertension as a cause of cardiovascular dysfunction.
Glen SK, Elliott HL, Curzio JL, Lees KR, Reid JL.
Lancet. 1996 Sep 7;348(9028):654-7. doi: 10.1016/S0140-6736(96)02303-3.
The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.
Sanidas E, Tsakalis K, Papadopoulos DP, Zerva K, Velliou M, Perrea D, Mantzourani M, Iliopoulos D, Barbetseas J.
J Clin Hypertens (Greenwich). 2019 Jan;21(1):48-52. doi: 10.1111/jch.13449. Epub 2018 Dec 7.
